Production of Influenza Vaccine Using Vero Cells
Author Information
Author(s): Chen Allen, Poh Swan Li, Dietzsch Christian, Roethl Elisabeth, Yan Mylene L, Ng Say Kong
Primary Institution: Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR)
Hypothesis
Can Vero cells be used in a scalable bioreactor process for the production of a replication-deficient Influenza vaccine candidate virus?
Conclusion
The study successfully demonstrates the production of Influenza viruses using Vero cells in serum-free medium, providing a scalable platform for vaccine production.
Supporting Evidence
- EX-CELL Vero SFM achieved the highest cell concentration of 2.6 × 10^6 cells/ml.
- A virus yield of 7.6 Log10 TCID50/ml was achieved using specific conditions.
- The bioreactor system produced high virus titres of up to 10 Log10 TCID50/ml.
- Time points for infection had no significant effect on final virus titres.
- Production of ΔNS1 H1N1 virus was compared to wild type H1N1 virus.
Takeaway
This study shows how scientists can grow a special type of flu virus in cells without using animal products, which can help make vaccines more easily.
Methodology
The study evaluated five serum-free media for Vero cell growth and scaled up the production process in a bioreactor.
Potential Biases
Potential bias in media selection and the specific conditions used for virus production.
Limitations
The study primarily focused on one type of cell line and specific media, which may limit generalizability.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website